Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Exploring the self-reported motivations of kratom (Mitragyna speciosa Korth.) use: a cross-sectional investigation
Oliver Grundmann, Charles A. Veltri, Diana Morcos, et al.
The American Journal of Drug and Alcohol Abuse (2022) Vol. 48, Iss. 4, pp. 433-444
Closed Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Ecological Momentary Assessment of Self-Reported Kratom Use, Effects, and Motivations Among US Adults
Kirsten E. Smith, Leigh V. Panlilio, Jeffrey D. Feldman, et al.
JAMA Network Open (2024) Vol. 7, Iss. 1, pp. e2353401-e2353401
Open Access | Times Cited: 14
Kratom safety and toxicology in the public health context: research needs to better inform regulation
Jack E. Henningfield, Oliver Grundmann, Marilyn A. Huestis, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 11
Examining the paradoxical effects of kratom: a narrative inquiry
Kirsten E. Smith, Jeffrey D. Feldman, Kelly E. Dunn, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 20
Clinical Implications of Kratom (Mitragyna speciosa) Use: a Literature Review
Elisabeth Prevete, Kim P. C. Kuypers, Eef L. Theunissen, et al.
Current Addiction Reports (2023) Vol. 10, Iss. 2, pp. 317-334
Open Access | Times Cited: 17
Correlations of kratom (Mitragyna speciosa Korth.) use behavior and psychiatric conditions from a cross-sectional survey.
Oliver Grundmann, Charles A. Veltri, Sara Morcos, et al.
Experimental and Clinical Psychopharmacology (2023) Vol. 31, Iss. 5, pp. 963-977
Open Access | Times Cited: 14
Prevalence and Use Patterns of Kratom ( Mitragyna speciosa Korth.) in a US Nationally Representative Sample
Oliver Grundmann, MeShell Green, Erin C. Berthold, et al.
Journal of Psychoactive Drugs (2025), pp. 1-9
Closed Access
Modern perspectives on psychoses: dissociation, automatism, and temporality across exogenous and endogenous dimensions
Valerio Ricci, Maria Celeste Ciavarella, Carlotta Marrangone, et al.
Frontiers in Psychiatry (2025) Vol. 16
Open Access
Omissions, Ambiguities, and Underuse of Causal Assessment Tools: a Systematic Review of Case Reports on Patients Who Use Kratom
Jeffrey D. Feldman, Destiny Schriefer, Kirsten E. Smith, et al.
Current Addiction Reports (2023) Vol. 10, Iss. 2, pp. 293-303
Closed Access | Times Cited: 11
Kratom’s Emergence and Persistence Within the US Polydrug Epidemic
Kirsten E. Smith, Jeffrey M. Rogers, Jeffrey D. Feldman
Current Addiction Reports (2023) Vol. 10, Iss. 2, pp. 262-271
Open Access | Times Cited: 10
Novel methods for the remote investigation of emerging substances: Application to kratom.
Kirsten E. Smith, Jeffrey D. Feldman, Kelly E. Dunn, et al.
Experimental and Clinical Psychopharmacology (2023) Vol. 32, Iss. 2, pp. 215-227
Open Access | Times Cited: 10
Cannabidiol and mitragynine exhibit differential interactive effects in the attenuation of paclitaxel-induced mechanical allodynia, acute antinociception, and schedule-controlled responding in mice
Yuma T. Ortiz, Joshua A. Bilbrey, Jasmine S. Felix, et al.
Pharmacological Reports (2023) Vol. 75, Iss. 4, pp. 937-950
Closed Access | Times Cited: 10
Diagnostic Ambiguities and Underuse of Clinical Assessment Tools: A Systematic Review of Case Reports on Kratom Addiction and Physical Dependence
Kirsten E. Smith, Jeffrey D. Feldman, Destiny Schriefer, et al.
Current Addiction Reports (2023) Vol. 10, Iss. 2, pp. 282-292
Closed Access | Times Cited: 9
Pharmacokinetic Interaction of Kratom and Cannabidiol in Male Rats
Erin C. Berthold, Shyam H. Kamble, Raju S. Kanumuri, et al.
Pharmaceutics (2024) Vol. 16, Iss. 3, pp. 318-318
Open Access | Times Cited: 3
Commentary: Presence of kratom in opioid overdose deaths: findings from coroner postmortem toxicological report
Oliver Grundmann, Kirsten E Smith, Walter C. Prozialeck, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 3
Rethinking Mental Automatism: De Clérambault’s Theory in the Age of Novel Psychoactive Drugs: Psychotropic Effects and Synthetic Psychosis
Valerio Ricci, Giuseppe Maina, Giovanni Martinotti
Healthcare (2024) Vol. 12, Iss. 12, pp. 1172-1172
Open Access | Times Cited: 2
Kava (Piper methysticum) in the United States: the quiet rise of a substance with often subtle effects
Salma Pont-Fernandez, Marina Kheyfets, Jeffrey M. Rogers, et al.
The American Journal of Drug and Alcohol Abuse (2022) Vol. 49, Iss. 1, pp. 85-96
Closed Access | Times Cited: 11
Associations Between Kratom-Related State Policy Environments and Kratom Use in a Nationally Representative Population in the United States
Matthew S. Ellis, Mance E. Buttram, Alyssa Forber, et al.
Journal of Psychoactive Drugs (2023) Vol. 56, Iss. 3, pp. 333-341
Closed Access | Times Cited: 6
Examining the Psychoactive Differences between Kratom Strains
Guido Huisman, Maximilian Menke, Oliver Grundmann, et al.
International Journal of Environmental Research and Public Health (2023) Vol. 20, Iss. 14, pp. 6425-6425
Open Access | Times Cited: 6
Research and publication gaps on kratom and kratom products: a scoping review of current literature
Balasingam Vicknasingam, Thiruventhan Karunakaran, Marek C. Chawarski
Current Opinion in Psychiatry (2024) Vol. 37, Iss. 4, pp. 282-291
Closed Access | Times Cited: 1
Time course of kratom effects via ecological momentary assessment, by product type, dose amount, and assayed alkaloid content
Kirsten E. Smith, Leigh V. Panlilio, Abhisheak Sharma, et al.
Drug and Alcohol Dependence (2024) Vol. 264, pp. 112460-112460
Open Access | Times Cited: 1
Cannabinoid mechanisms contribute to the therapeutic efficacy of the kratom alkaloid mitragynine against neuropathic, but not inflammatory pain
Daniel Farkas, Saadet Inan, Laila N. Heydari, et al.
Life Sciences (2023) Vol. 328, pp. 121878-121878
Closed Access | Times Cited: 4
A Preliminary Inventory of Kratom (Mitragyna Speciosa) Products and Vendors on the Darknet and Cryptomarkets
Elisabeth Prevete, Valeria Catalani, Darshan Singh, et al.
Journal of Psychoactive Drugs (2023) Vol. 56, Iss. 4, pp. 485-495
Closed Access | Times Cited: 4
Kratom Alkaloids, Cannabinoids, and Chronic Pain: Basis of Potential Utility and Role in Therapy
Daniel Farkas, Ziva D. Cooper, Laila N. Heydari, et al.
Cannabis and Cannabinoid Research (2023)
Closed Access | Times Cited: 3
Kratom ( Mitragyna speciosa ) use in a sample of drug-dependent adolescents in rehabilitation for drug use in Malaysia
Darshan Singh, Mohd Aizuddin Azuan, Suresh Narayanan
Journal of Ethnicity in Substance Abuse (2023), pp. 1-16
Closed Access | Times Cited: 3
Kratom (Mitragyna Speciosa) Use for Self-Management of Pain: Insights from Cross-Sectional and Ecological Momentary Assessment Data
Chung Jung Mun, Leigh V. Panlilio, Kelly E. Dunn, et al.
Journal of Pain (2024) Vol. 26, pp. 104726-104726
Closed Access
Page 1 - Next Page

Scroll to top